AzTrials
AzTrials

Peritoneal Dialysis-associated PeritonitisNCT00801775

Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry

An observational study of Peritoneal Dialysis-associated Peritonitis, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to analyze whether calorimetry compared to conventional methods (i.e.blood culture systems)is superior to diagnose peritoneal dialysis related peritonitis. Read more about this study

Who is it for?
Any age
How many people
8 participants
Where
1 siteSwitzerland
Study dates
Aug 2008to Mar 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients on peritoneal dialysis

Who may be able to join

  • all patients on peritoneal dialysis

Who cannot join

  • none

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Universitätsspital Basel

    Basel, 4031

Other trials in Switzerland

About this study

The purpose of this study is to analyze whether calorimetry compared to conventional methods (i.e.blood culture systems)is superior to diagnose peritoneal dialysis related peritonitis.

Read the detailed description

Background:

Peritonitis is still considered the most important complication of peritoneal dialysis (PD) associated with high mortality, therapy failure, and healthcare expenses. We have recently demonstrated that peritonitis continuous to be the most common reason for technical failure in PD contributing equally to early and late failure; 12 of 279 patients died as a consequence of PD associated peritonitis. The diagnosis of peritonitis is typically based on clinical symptoms, which reflects an already advanced state of inflammation and disease. Since the implementation of the blood culture system for detection of bacterial growth in PD effluent more than ten years ago, no considerable progress has been made to improve diagnosis of PD associated peritonitis. In our own PD population 36 out of 219 (16%) infectious peritonitis episodes were culture-negative. Usually, detection time of microorganisms requires at least 12 hours and time to pathogen identification more than 48 hours. Rapidly dividing cells such as bacteria produce heat, which can be measured by calorimetry. As recently shown, by our research group, calorimetry allows rapid and accurate diagnosis of bacterial growth in cases of meningitis and in contaminated platelets. In pilot experiments, we could show the potential and the feasibility of calorimetry for early and accurate detection of microorganisms in PD fluid.

Hypothesis and aims:

We hypothesize that calorimetry of PD effluent can significantly improve the diagnosis of PD associated peritonitis by early and accurate detection of pathogens. As compared to traditional culture methods, calorimetry may (i) have a shorter time to positivity and (ii) a higher sensitivity without loss of specificity. Specific aims are to evaluate if calorimetry: (i) is more rapid in detection of microorganisms compared to conventional blood cultures, (ii) is superior, regarding sensitivity and specificity, in detection of PD associated peritonitis compared to the standard blood culture system and (iii) is a valuable tool for pathogen identification by specific heat signal "signatures" received by calorimetry. The Primary endpoint is the time to positivity of bacterial growth by calorimetry and conventional blood cultures. The secondary endpoints are the accuracy (i.e. sensitivity and specificity) of detection rates of microorganism in PD fluid and the rate of consistency of pathogen identification between calorimetry curves and conventional microbiological method.

Research plan:

After obtaining informed consent, we will prospectively include in this open-labeled comparative study all patients aged 16 years or older, who are performing PD at the University Hospital in the time period from January 2009 through December 2011. PD fluid will be submitted for conventional screening examination (cell count and differential) and calorimetry (sterile MonovetteR tube) during routine visit. If PD peritonitis is suspected, PD fluid will be also inoculated in aerobic and anaerobic culture bottles at bedside under sterile conditions, each bottle with 10 ml of PD fluid. For calorimetry, 1 ml PD fluid will be cultivated at 37°C in the calorimeter tubes, containing 2 ml of trypticase soy broth (TSB). Conventional culture bottles and calorimeter tubes are incubated for a total of 6 days, after which culture and/or calorimetry are regarded negative. Medical records will be prospectively abstracted for demographic characteristics, clinical, radiographic, laboratory and microbiological data using a standardized case report form. The sample size calculation was performed separately for primary and secondary endpoints on the following settings: 0.05, power 80%, two-sided test. To reach statistical significant differences for the primary endpoint, 286 samples are required for the study. For the secondary endpoint with p0 = 80% (sensitivity of conventional blood cultures), p1 = 95% (sensitivity of calorimetry cultures), 255 samples are required. With an expected drop-out rate of 5%, approximately 300 samples will be needed. With expected 120-180 samples/year study duration of approximately 2.5 to 3 years is needed.

Expected outcome:

We anticipate that calorimetry will significantly improve the diagnosis of PD-associated peritonitis. First (primary endpoint), we predict an earlier pathogen detection by calorimetry; second (secondary endpoint), we expect to increase the sensitivity by 15% without loss of specificity (>90%). Furthermore, we assume that the most important pathogens, seen in our PD population (i.e. S. aureus, coagulase-negative staphylococci, streptococci, enterobacteriaceae) may be identified within 12 hours (compared to > 48 hours by conventional microbiological methods) with an accuracy of 80%. The ultra-sensitive calorimetry technique may diagnose PD associated peritonitis in an early disease stage with high accuracy. This would be the basis of a rapid and targeted antibiotic therapy, which may significantly influence the outcome of these patients.

Keywords
calorimetry

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. First (primary endpoint), we predict an earlier pathogen detection by calorimetry (<6 hours versus >24 hours)

    Measured: two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Dec 2008 (estimated)
  2. Study startAug 2008
  3. Primary completionMar 2009
  4. Study completionMar 2009

Why it stopped: The study was stopped march 2009 due to recruitment problems.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00801775
Sponsor's protocol ID
Mayr-PD-01
Status last verified
Jun 2011
First submitted
3 Dec 2008
Last updated
13 Jun 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Peritoneal Dialysis-associated Peritonitis, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 13 Jun 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: The study was stopped march 2009 due to recruitment problems.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

First (primary endpoint), we predict an earlier pathogen detection by calorimetry (<6 hours versus >24 hours) (time frame: two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in